Current stage -Stage III - Page 2 of 8 Posts on Medivizor
Navigation Menu

Current stage -Stage III Posts on Medivizor

2018 recommendations for the treatment of localized prostate cancer: Part II

Posted by on Sep 25, 2018 in Prostate cancer | 0 comments

In a nutshell This article reviewed treatment guidelines that have been recommended for patients with early-stage prostate cancer. Some background This analysis of existing treatment guidelines was done by the leading experts in prostate cancer research. They have made recommendations on the treatment of early-stage prostate cancer.  Methods...

Read More

Comparing daily versus weekly imaging checks in radiation therapy for prostate cancer

Posted by on Aug 26, 2018 in Prostate cancer | 0 comments

In a nutshell This study aimed to investigate the best timing of treatment verification imaging used in radiation therapy for patients with prostate cancer. This study found that patients undergoing daily imaging had less risk of their cancer returning and had reduced rectal side-effects. Some background One main treatment option for prostate cancer...

Read More

PSA response after cabazitaxel treatment is associated with improved progression-free survival in men with metastatic castration-resistant prostate cancer.

Posted by on Jan 26, 2018 in Prostate cancer | 0 comments

In a nutshell This study aimed to examine the links between prostate specific antigen (PSA, a protein present in prostate cancer) and survival in patients with metastatic castration-resistant prostate cancer treated with cabazitaxel. This studty concluded that PSA response after cabazitaxel treatment is associated with improved...

Read More

Looking for men with high-risk prostate cancer to test whether apalutamide improves surgery outcomes

Posted by on Dec 5, 2017 in Prostate cancer | 0 comments

In a nutshell The aim of this trial is to determine the effect of the hormone therapy apalutamide (ARN-509) with or without abiraterone acetate (Zytiga), GnRH agonists or prednisone and whether they improve prostate surgery outcomes in men with high-risk prostate cancer. The outcomes to be measured include erectile function, continence, and effect on...

Read More

Looking for men with castration-resistant prostate cancer to test ipatasertib plus abiraterone/prednisone

Posted by on Dec 5, 2017 in Prostate cancer | 0 comments

In a nutshell The aim of this study is to determine the effectiveness and safety of ipatasertib (GDC-0068) in combination with abiraterone (Zytiga) and prednisone/prednisolone (Deltasone) in men with metastatic castration-resistant prostate cancer. The main outcome to be measured is time to disease progression. The details Metastatic prostate...

Read More

Searching for patients to test the effectiveness of docetaxel and carboplatin in the treatment of advanced prostate cancer

Posted by on Jun 6, 2017 in Prostate cancer | 0 comments

In a nutshell The aim of this trial is to determine the effectiveness of a combination of the chemotherapies docetaxel (Taxotere) and carboplatin (Paraplatin) in advanced (spread beyond the prostate) prostate cancer. The main outcome to be measured is the number of patients who experience a decrease of 50% in prostate specific...

Read More

Can radiation and hormone therapy after surgery improve prostate cancer survival rates?

Posted by on Jan 21, 2017 in Prostate cancer | 1 comment

In a nutshell The aim of this study was to determine whether radiation therapy in combination with hormonal therapy improved survival in men with prostate cancer that has spread to the lymph nodes after surgery. Researchers concluded that patients treated with radiation therapy and hormone therapy had a significantly higher survival rate compared to...

Read More

High-risk prostate cancer: Is there a survival benefit when chemotherapy is administered before surgery?

Posted by on Nov 28, 2016 in Prostate cancer | 0 comments

In a nutshell This study examined the benefit of administering chemotherapy before prostate surgery in men with intermediate- to high-risk prostate cancer. Researchers reported preliminary evidence of a cancer-specific survival benefit when chemotherapy was administered before surgery. Some background Prostate surgery is a first-line treatment for...

Read More

Survival benefit when adding radiation therapy to hormone therapy for metastatic prostate cancer

Posted by on Nov 7, 2016 in Prostate cancer | 0 comments

In a nutshell The aim of this study was to examine the benefit of adding radiation therapy to androgen deprivation therapy (ADT) for metastatic prostate cancer. Researchers reported a significant survival advantage when radiation therapy was combined with ADT. Some background Metastatic prostate cancer is cancer that has spread from the prostate...

Read More